Addex Therapeutics (ADXN) Return on Capital Employed (2020 - 2026)
Addex Therapeutics (ADXN) posted Return on Capital Employed of 61.24% for Q1 2026, down 27.04% sequentially from 48.2% in Q4 2025, and down 697.0% YoY from 10.26% in Q1 2025.
Addex Therapeutics (ADXN) Return on Capital Employed (2020 - 2026) Analysis & Trends
Addex Therapeutics has reported Return on Capital Employed for 7 years, with the latest figure at 61.24% in Q1 2026.
- Quarterly Return on Capital Employed fell 697.0% year-over-year to 61.24% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 61.24% (down 697.0% YoY) and the FY2025 annual result came in at 40.12%, up 16.0% from the prior year.
- Return on Capital Employed eased to 61.24% in Q1 2026 per ADXN's latest filing, from 48.2% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 586.3% in Q1 2024 and troughed at 695.9% in Q1 2023.
- A 5-year average of 175.35% and a median of 67.57% in 2025 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed jumped 128220 bps in 2024, then slumped 64057 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 542.49% in 2022, then jumped by 73 bps to 148.97% in 2023, then surged by 68 bps to 47.21% in 2024, then retreated by 2 bps to 48.2% in 2025, then fell by 27 bps to 61.24% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 61.24%, 48.2%, and 67.57% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Addex Therapeutics | 534.71 Mn | 534.71 Mn | - | -61.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -61.24% |
| Dec 31, 2025 | -48.20% |
| Sep 30, 2025 | -67.57% |
| Jun 30, 2025 | -60.10% |
| Mar 31, 2025 | -54.27% |
| Dec 31, 2024 | -47.21% |
| Sep 30, 2024 | -37.91% |
| Jun 30, 2024 | -62.48% |
| Mar 31, 2024 | 586.30% |
| Dec 31, 2023 | -148.97% |
| Sep 30, 2023 | -365.31% |
| Jun 30, 2023 | -446.17% |
| Mar 31, 2023 | -695.90% |
| Dec 31, 2022 | -542.49% |
| Sep 30, 2022 | -435.72% |
| Jun 30, 2022 | -311.35% |
| Mar 31, 2022 | -182.30% |
| Dec 31, 2021 | -165.78% |
| Sep 30, 2021 | -143.05% |
| Jun 30, 2021 | -112.02% |